NEJM: a targeted combination therapy may make postmenopausal patients with malignant breast cancer live longer!

January 6, 2020 / Biovalley / recently, a research report published in the International Journal New England Journal of medicine, scientists from the University of California found that adding targeted drug ribociclib to standard kininotherapy could significantly improve postmenopausal hormone receptor positive / HER2 negative breast cancer Overall survival rate of patients Photo source: Milo Mitchell / UCLA related research results show that this combination therapy can effectively play a therapeutic effect in patients with cancer recurrence, and it is also expected to become the primary treatment for postmenopausal hormone receptor positive / HER2 negative breast cancer patients; researcher Dennis Many people think that the first treatment for patients with this kind of metastatic breast cancer is to choose other forms of hormone therapy However, it is necessary to observe whether this kind of therapy is effective or not However, we found that the combination of ribesinib and standard hormone therapy as a first-line treatment for this kind of breast cancer patients will produce unexpected therapeutic effects, which is a combination of Treatment is expected to be the standard treatment for this type of breast cancer Rebesinib is a special kind of drug, which belongs to the family of CDK4 / 6 inhibitors The inhibitor can play a role by blocking the activity of cyclin dependent kinase 4 / 6 (CDK4 / 6), which can promote cell division and cancer growth The results of this study are based on the previous research findings of the researchers At present, the drug rebesinib has been approved by the FDA The researchers pointed out that the FDA approved the combination of three CDK4 / 6 inhibitors and standard hormone therapy In this double-blind trial, the researchers included 726 postmenopausal women with hormone receptor positive / HER2 negative breast cancer who had not previously received endocrine therapy, as well as first-line and second-line therapy The results of the related studies showed that the survival rate of the patients receiving the new combined therapy was significantly improved, and the risk of death was reduced by 28% At the 42nd month, the survival rate of the patients receiving the combined therapy was about 58%, while the survival rate of the patients receiving the hormone therapy alone was 46% In phase III clinical trials The median progression free survival was 33.6 months in the first-line group and 19.2 months in the hormone group alone This study is the first to show that women with postmenopausal breast cancer can gain overall survival advantage when receiving this new therapy The second study showed that the drug can increase the overall survival rate of the patients, but But few experiments can be done Increasing the overall survival rate of the patient population is the most difficult end point to move, said researcher slamon We also found that the disease progression free survival period of patients treated with this new therapy is the longest so far; even if patients do not take the medicine, the effect of the medicine can last for a long time, which is very important, because it may help improve the postmenopausal mammary gland Life span and quality of life of cancer patients Currently, researchers plan to evaluate the efficacy of these drugs in early stage breast cancer patients in an international clinical trial, which is jointly sponsored by Novartis and other institutions Original sources: Dennis J slamon, M.D., Ph.D., Patrick neven, M.D., Ph.D., Stephen Chia, M.D., et al Overall survival with ribociclib plus fulvestrant in advanced bread cancer, NEJM, December 11, 2019 doi: 10.1056/nejmoa1911149